|
Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial. |
|
|
Honoraria - Alkermes; Amgen; EMD Serono; Merck; Prometheus; Sanofi Pasteur |
Consulting or Advisory Role - Alkermes; Amgen; Merck; Merck Serono; Prometheus |
|
Research Funding - Bristol-Myers Squibb/Medarex |
Travel, Accommodations, Expenses - Alkermes; EMD Serono; Sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Merck |
Research Funding - Merck (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - Amgen; EMD Serono |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Novartis; Roche |
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - EMD Serono (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Research Funding - EMD Serono |
|
|
|
|
|
|
Stock and Other Ownership Interests - Merck KGaA |
|
|
|
|
|
Travel, Accommodations, Expenses - EMD Serono |